We have long argued that by the time 2nd Generation CAR T cell therapies hit the market they will almost be obsolete and next generation versions will already be in advanced clinical testing. The product life cycle in this niche is likely to be a very rapid one, much more so than in other areas of cancer research.

The critical question isn’t when these new constructs will be available, but rather what form will they take? What will they look like, and which issues will they address?

Several researchers are leading the way in the CAR T cell therapy space, but a recent presentation by one expert in this field reinforced how he is making a transition from pioneer to disruptor.

In this post we explore some of the issues and ideas he discussed in a vision for the future.

To learn more, subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.

This content is restricted to subscribers